drugset / Trial / NCT01884428
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
study to assess maximum tolerated dose (MTD), safety, tolerability and activity of IGEV (Ifosfamide, Gemcitabine,Vinorelbine, Prednisolone) + Panobinostat new combination in order to determine the recommended phase II dose
Timeline
- Start
- 2011-07
- Primary completion
- 2014-03
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 10 mg | Oral |
| Subject | Panobinostat | Small molecule | 20 mg | Oral |
| Background | Gemcitabine | Small molecule | 800 mg/m2 | — |
| Background | Ifosfamide | Small molecule | 2000 mg/m2 | — |
| Background | Prednisolone | Other / unclassified | 100 mg | — |
| Background | Vinorelbine | Small molecule | 20 mg/m2 | — |